CASTOR2

Across TCGA pan-cancer cohorts, CASTOR2 mass-spec protein differs between tumor and matched normal tissue in 3 of 18 cancer types tested, making tumor–normal expression one of CASTOR2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where CASTOR2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types CASTOR2 is over-expressed in tumor, although a few such as HNSC and LUAD show the opposite, repressed pattern.

HNSC, LSCC, and LUAD are the cancer types where CASTOR2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CASTOR2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	II,III,IV	−0.250	<.001	7	view →
LSCC	All	All	+0.113	.003	4	view →
LUAD	All	All	−0.140	.004	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 3 strongest of 3 lineages.

CASTOR2–HNSC

Open the HNSC breakdown →